Metabolic
11 drugs are in development for Obesity.
- Companies
- 9
- Clinical trials
- 338
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Obesity pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Approved(2)
| Drug | Company |
|---|---|
| contrave | Orexigen Therapeutics, Inc. (OREX) |
| mysimba | Orexigen Therapeutics, Inc. (OREX) |
Phase 2(2)
| Drug | Company |
|---|---|
| kai-7535 | Kailera Therapeutics, Inc. (KLRA) |
| nimacimab | Skye Bioscience, Inc. (SKYE) |
Phase 1(3)
| Drug | Company |
|---|---|
| BMF-650 | Biomea Fusion, Inc. (BMEA) |
| da-1726 | MetaVia Inc. (MTVA) |
| rt-114 | Rani Therapeutics Holdings, Inc. (RANI) |
Preclinical(2)
| Drug | Company |
|---|---|
| oral oxm | Entera Bio Ltd. (ENTX) |
| sln098 | Silence Therapeutics Plc (SLN) |
Phase 4(2)
About this indication
Obesity context
Metabolic·MeSH: Obesity (D009765)
Prevalence
42000.0 / 100K
Incidence
2000.0 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Obesity?
BioSniper tracks 11 drugs in development for Obesity across 9 companies.
How many clinical trials target Obesity?
There are 338 clinical trials targeting Obesity tracked by BioSniper.
What is the prevalence of Obesity?
The estimated prevalence of Obesity is approximately 42000.0 per 100,000 population.